| 摘要 |
The present invention is based on the discovery that in patients infected with Hepatitis C Virus Genotype 1 (HCV-1) or Genotype 4 (HCV-4), a beneficial response to a treatment that includes interferon alpha, ribavirin and a HCV polymerase inhibitor could be predicted if the patient's HCV RNA level becomes undetectable in as short as two weeks post treatment.
|
